Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)
BJU International · 2024-12 · 134 (6) · 967-975
DOI: 10.1111/bju.16526 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift BJU International, online erschienen am 12.09.2024. Verfasst von Francesco Ditonno und 36 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Rush University, Chicago, IL, USA. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Nephroureterectomy, Robotic Surgical Procedures. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
To analyse surgical, functional, and mid‐term oncological outcomes of robot‐assisted nephroureterectomy (RANU) in a contemporary large multi‐institutional setting. Patients and Methods Data were retrieved from the ROBotic surgery for Upper tract Urothelial cancer STtudy (ROBUUST) 2.0 database, an international, multicentre registry encompassing data of patients with upper urinary tract urothelial carcinoma undergoing curative surgery between 2015 and 2022. The analysis included all consecutive patients undergoing RANU except those with missing data in predictors. Detailed surgical, pathological, and postoperative functional data were recorded and analysed. Oncological time‐to‐event outcomes were: recurrence‐free survival (RFS), metastasis‐free survival (MFS), cancer‐specific survival (CSS), and overall survival (OS). Survival analysis was performed using the Kaplan–Meier method, with a 3‐year cut‐off. A multivariable Cox proportional hazard model was built to evaluate predictors of each oncological outcome.
Results
A total of 1118 patients underwent RANU during the study period. The postoperative complications rate was 14.1%; the positive surgical margin rate was 4.7%. A postoperative median (interquartile range) estimated glomerular filtration rate decrease of −13.1 (−27.5 to 0) mL/min/1.73 m 2 from baseline was observed. The 3‐year RFS was 59% and the 3‐year MFS was 76%, with a 3‐year OS and CSS of 76% and 88%, respectively. Significant predictors of worse oncological outcomes were bladder‐cuff excision, high‐grade tumour, pathological T stage ≥3, and nodal involvement.
Conclusions
The present study contributes to the growing body of evidence supporting the increasing adoption of RANU. The procedure consistently offers low surgical morbidity and can provide favourable mid‐term oncological outcomes, mirroring those of open NU, even in non‐organ‐confined disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Rush University, Chicago, IL, USA.
- Department of Urology, University of Verona, Verona, Italy.
- Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.
- Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.
- Department of Urology, IRCCS "Regina Elena" National Cancer Institute, Rome, Italy.
- Department of Urology, Fox Chase Cancer Center, Philadelphia, PA, USA.
ORCID-Profile: Francesco Ditonno, Zhenjie Wu, Linhui Wang, Giuseppe Simone, Matteo Ferro, Daniele Amparore, Dhruv Puri, Reuben Ben-David, Alireza Ghoreifi, Gabriele Tuderti, Soroush Rais-Bahrami, Ithaar H Derweesh, Francesco Porpiglia, Vitaly Margulis, Alessandro Antonelli, Hooman Djaladat, Riccardo Autorino
Zitieren
APA
Ditonno, F., Franco, A., Wu, Z., Wang, L., Abdollah, F., Simone, G., Correa, A. F., Ferro, M., Perdonà, S., Amparore, D., Bhanvadia, R., Brönimann, S., Puri, D., Mendiola, D. F., Ben-David, R., Moon, S. C., Yong, C., Moghaddam, F. S., Ghoreifi, A., …, & Autorino, R. (2024). Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group). BJU International, 134(6), 967-975. https://doi.org/10.1111/bju.16526
Vancouver
Ditonno F, Franco A, Wu Z, Wang L, Abdollah F, Simone G, et al. Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group). BJU International. 2024;134(6):967-975. doi:10.1111/bju.16526
BibTeX
@article{Ditonno2024,
author = {Ditonno, Francesco and Franco, Antonio and Wu, Zhenjie and Wang, Linhui and Abdollah, Firas and Simone, Giuseppe and Correa, Andres F and Ferro, Matteo and Perdonà, Sisto and Amparore, Daniele and Bhanvadia, Raj and Brönimann, Stephan and Puri, Dhruv and Mendiola, Dinno F and Ben-David, Reuben and Moon, Sol C and Yong, Courtney and Moghaddam, Farshad S and Ghoreifi, Alireza and Bologna, Eugenio and Licari, Leslie Claire and Finati, Marco and Tuderti, Gabriele and Helstrom, Emma and Tozzi, Marco and Tufano, Antonio and Rais-Bahrami, Soroush and Sundaram, Chandru P and Mehrazin, Reza and Gonzalgo, Mark L and Derweesh, Ithaar H and Porpiglia, Francesco and Singla, Nirmish and Margulis, Vitaly and Antonelli, Alessandro and Djaladat, Hooman and Autorino, Riccardo},
title = {Robot‐assisted nephroureterectomy: surgical and mid‐term oncological outcomes in over 1100 patients (ROBUUST 2.0 collaborative group)},
journal = {BJU International},
year = {2024},
volume = {134},
number = {6},
pages = {967--975},
doi = {10.1111/bju.16526}
}
EUVIMED